U.S. Periodontal Treatment for Adults Market – Industry Trends and Forecast to 2032

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE U.S. PERIODONTAL TREATMENT FOR ADULTS MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 DBMR TRIPOD DATA VALIDATION MODEL

2.3 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.4 DBMR MARKET POSITION GRID

2.5 VENDOR SHARE ANALYSIS

2.6 SECONDARY SOURCES

2.7 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PORTER’S FIVE FORCES

4.2 PESTEL ANALYSIS

5 U.S. PERIODONTAL TREATMENT FOR ADULTS MARKET: REGULATIONS

5.1 REGULATORY AUTHORITIES IN THE U.S.

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 EXPANSION OF DENTAL INSURANCE COVERAGE FOR PERIODONTAL CARE

6.1.2 IMPROVED PATIENT EDUCATION ON THE IMPORTANCE OF PERIODONTAL HEALTH AND CARE

6.1.3 CONNECTION BETWEEN ORAL HEALTH AND SYSTEMIC DISEASES IMPACTING OVERALL HEALTH

6.2 RESTRAINTS

6.2.1 HIGH TREATMENT COSTS LIMITING ACCESS TO PERIODONTAL CARE FOR ADULTS

6.2.2 COMPLEXITY OF TREATMENT PROTOCOLS INCREASING CHALLENGES IN PERIODONTAL CARE

6.3 OPPORTUNITIES

6.3.1 EMERGING TREATMENTS FOR COMPLEX PERIODONTAL DISEASE

6.3.2 INCREASING IMPORTANCE OF PERIODONTAL CARE

6.3.3 GROWING ADOPTION OF AI AND MACHINE LEARNING IN PERIODONTAL DIAGNOSTICS

6.4 CHALLENGES

6.4.1 LIMITED AWARENESS OF THE PERIODONTAL TREATMENTS

6.4.2 SHORTAGE OF QUALIFIED PERIODONTAL SPECIALISTS

7 U.S. PERIODONTAL TREATMENT FOR ADULTS MARKET, BY PRODUCT TYPE

7.1 OVERVIEW

7.2 REGENERATIVE BIOMATERIALS

7.2.1 BONE GRAFTS

7.2.2 MEMBRANES FOR GUIDED BONE/TISSUE REGENERATION (GBR/GTR)

7.3 ANTIBIOTICS AND ANTIMICROBIALS

8 U.S. PERIODONTAL TREATMENT FOR ADULTS MARKET, BY PRACTICE TYPE

8.1 OVERVIEW

8.2 PRIVATE PRACTICE

8.2.1 REGENERATIVE BIOMATERIALS

8.2.1.1 BONE GRAFTS

8.2.1.1.1 ALLOGRAFT

8.2.1.1.2 XENOGRAFT

8.2.1.1.3 SYNTHETIC BONE GRAFTS

8.2.1.2 MEMBRANES FOR GUIDED BONE/TISSUE REGENERATION (GBR/GTR)

8.2.1.2.1 RESORBABLE MEMBRANES

8.2.1.2.2 NON-RESORBABLE MEMBRANES

8.3 ANTIBIOTICS AND ANTIMICROBIALS

8.3.1 LOCAL ANTIBIOTIC

8.3.2 SYSTEMIC ANTIBIOTIC THERAPY

8.3.2.1 ORAL ANTIBIOTICS

8.3.2.1.1 DOXYCYCLINE

8.3.2.1.2 AMOXICILLIN

8.3.2.1.3 METRONIDAZOLE

8.3.2.1.4 CLINDAMYCIN

8.3.2.1.5 AZITHROMYCIN

8.3.2.1.6 VIBRAMYCIN

8.3.2.1.7 OTHERS

8.3.2.2 TOPICAL ANTIBIOTICS

8.3.2.2.1 MINOCYCLINE HYDROCHLORIDE (ARESTIN)

8.3.2.2.2 CHLORHEXIDINE

8.3.2.2.3 DOXYCYCLINE

8.3.2.2.4 METRONIDAZOLE GEL

8.3.2.2.5 OTHERS

8.4 DSO (DENTAL SERVICE ORGANIZATIONS)

8.4.1 REGENERATIVE BIOMATERIALS

8.4.1.1 BONE GRAFTS

8.4.1.1.1 ALLOGRAFT

8.4.1.1.2 XENOGRAFT

8.4.1.1.3 SYNTHETIC BONE GRAFTS

8.4.1.2 MEMBRANES FOR GUIDED BONE/TISSUE REGENERATION (GBR/GTR)

8.4.1.2.1 RESORBABLE MEMBRANES

8.4.1.2.2 NON-RESORBABLE MEMBRANES

8.4.2 ANTIBIOTICS AND ANTIMICROBIALS

8.4.2.1 LOCAL ANTIBIOTIC

8.4.2.2 SYSTEMIC ANTIBIOTIC THERAPY

8.4.2.2.1 ORAL ANTIBIOTICS

8.4.2.2.1.1 DOXYCYCLINE

8.4.2.2.1.2 AMOXICILLIN

8.4.2.2.1.3 METRONIDAZOLE

8.4.2.2.1.4 CLINDAMYCIN

8.4.2.2.1.5 AZITHROMYCIN

8.4.2.2.1.6 VIBRAMYCIN

8.4.2.2.1.7 OTHERS

8.4.2.2.2 TOPICAL ANTIBIOTICS

8.4.2.2.2.1 MINOCYCLINE HYDROCHLORIDE (ARESTIN)

8.4.2.2.2.2 CHLORHEXIDINE

8.4.2.2.2.3 DOXYCYCLINE

8.4.2.2.2.4 METRONIDAZOLE GEL

8.4.2.2.2.5 OTHERS

9 U.S. PERIODONTAL TREATMENT FOR ADULTS MARKET, BY DISEASE TYPE

9.1 OVERVIEW

9.2 CHRONIC PERIODONTITIS

9.3 GINGIVITIS

9.4 AGGRESSIVE PERIODONTITIS

9.5 NECROTIZING PERIODONTAL DISEASES

9.6 OTHERS

10 COMPANY SHARE ANALYSIS: U.S.

11 SWOT ANALYSIS

12 COMPANY PROFILES

12.1 DENTSPLY SIRONA

12.1.1 COMPANY SNAPSHOT

12.1.2 REVENUE ANALYSIS

12.1.3 PRODUCT PORTFOLIO

12.1.4 RECENT DEVELOPMENTS

12.2 INSTITUT STRAUMANN AG

12.2.1 COMPANY SNAPSHOT

12.2.2 REVENUE ANALYSIS

12.2.3 PRODUCT PORTFOLIO

12.2.4 RECENT DEVELOPMENTS

12.3 MEDTRONIC

12.3.1 COMPANY SNAPSHOT

12.3.2 REVENUE ANALYSIS

12.3.3 PRODUCT PORTFOLIO

12.3.4 RECENT DEVELOPMENT

12.4 ORAPHARMA

12.4.1 COMPANY SNAPSHOT

12.4.2 PRODUCT PORTFOLIO

12.4.3 RECENT DEVELOPMENT

12.5 GSK PLC.

12.5.1 COMPANY SNAPSHOT

12.5.2 REVENUE ANALYSIS

12.5.3 PRODUCT PORTFOLIO

12.5.4 RECENT DEVELOPMENT

12.6 BIOHORIZONS

12.6.1 COMPANY SNAPSHOT

12.6.2 PRODUCT PORTFOLIO

12.6.3 RECENT DEVELOPMENT

12.7 BIOLASE INC.

12.7.1 COMPANY SNAPSHOT

12.7.2 REVENUE ANALYSIS

12.7.3 PRODUCT PORTFOLIO

12.7.4 RECENT DEVELOPMENT

12.8 BIOCOMPOSITES

12.8.1 COMPANY SNAPSHOT

12.8.2 PRODUCT PORTFOLIO

12.8.3 RECENT DEVELOPMENT

12.9 EPIEN MEDICAL, INC.

12.9.1 COMPANY SNAPSHOT

12.9.2 PRODUCT PORTFOLIO

12.9.3 RECENT DEVELOPMENT

12.1 FORWARD SCIENCE

12.10.1 COMPANY SNAPSHOT

12.10.2 PRODUCT PORTFOLIO

12.10.3 RECENT DEVELOPMENT

12.11 HIOSSEN

12.11.1 COMPANY SNAPSHOT

12.11.2 PRODUCT PORTFOLIO

12.11.3 RECENT DEVELOPMENT

12.12 LIFENET HEALTH

12.12.1 COMPANY SNAPSHOT

12.12.2 PRODUCT PORTFOLIO

12.12.3 RECENT DEVELOPMENT

12.13 NOBEL BIOCARE USA

12.13.1 COMPANY SNAPSHOT

12.13.2 PRODUCT PORTFOLIO

12.13.3 RECENT DEVELOPMENT

12.14 OSTEOGENICS BIOMEDICAL

12.14.1 COMPANY SNAPSHOT

12.14.2 PRODUCT PORTFOLIO

12.14.3 RECENT DEVELOPMENT

12.15 PERIO PROTECT

12.15.1 COMPANY SNAPSHOT

12.15.2 PRODUCT PORTFOLIO

12.15.3 RECENT DEVELOPMENT

12.16 PFIZER

12.16.1 COMPANY SNAPSHOT

12.16.2 REVENUE ANALYSIS

12.16.3 PRODUCT PORTFOLIO

12.16.4 RECENT DEVELOPMENT

12.17 ZIMVIE INC.

12.17.1 COMPANY SNAPSHOT

12.17.2 REVENUE ANALYSIS

12.17.3 PRODUCT PORTFOLIO

12.17.4 RECENT DEVELOPMENT

13 QUESTIONNAIRE

14 RELATED REPORTS